How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka Grover from J.P. Morgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.